10
Participants
Start Date
December 6, 2022
Primary Completion Date
September 25, 2024
Study Completion Date
September 25, 2024
Infusion of either NST or placebo at different blood glucose levels
In a randomized, double-blind crossover design, participants will undergo six experimental days with controlled plasma glucose levels, consisting of two euglycemic, two hyperglycemic (around 8mmol/l), and two hypoglycemic (around 2.5mmol/l) days, with each pair of similar days involving the administration of either saline (placebo) or NST.
Center for Clinical Metabolic Research, Gentofte Hospital, Hellerup
The Novo Nordisk Foundation Center for Basic Metabolic Research
OTHER
University Hospital, Gentofte, Copenhagen
OTHER